MBX Biosciences, Inc.

Home
MBX Biosciences, Inc.

At MBX Biosciences, our mission is to help people with endocrine and metabolic disorders live fuller and healthier lives. MBX is based in Carmel, Indiana.

We’re pioneering a pipeline of novel Precision Endocrine Peptides (PEPs) with clinically validated targets, established endpoints for regulatory approval, targeting significant unmet medical needs and large potential market opportunities. Our lead product candidate canvuparatide (MBX 2109), is in Phase 2 development for the treatment of chronic hypoparathyroidism (HP); MBX 1416, has recently completed a Phase 1 trial and is in development for the treatment of post-bariatric hypoglycemia (PBH); and we also are developing an obesity portfolio that includes MBX 4291, as well as multiple discovery and pre-clinical candidates in development. To learn more, please visit the Company website at www.mbxbio.com.

24/10/2025

During MBX’s recent Together Week, we had the privilege of welcoming back Andrea Ligler — a powerful voice in the Hypoparathyroidism (HP) community and a patient advocate whose story continues to inspire. Andrea offered a deeply personal update on her journey with HP, sharing not only the medical realities but also the daily challenges and triumphs that come with managing this rare condition.

At MBX, our team understands the burden of HP — but it’s through courageous storytellers like Andrea that these lessons come to life. Her lived experience reminds us that behind every diagnosis is a person, a family, and a future shaped by resilience and hope. We remain steadfast in our mission to amplify patient voices and help people with endocrine and metabolic disorders live fuller and healthier lives.

Stories like Andrea’s don’t just inform us — they move us to act with greater empathy, urgency, and purpose.

15/10/2025

We’d like to thank everyone who joined us for our presentation, as well as express our gratitude to the HypoPARAthyroidism Association, Inc. for hosting a fantastic event this past weekend!

It is especially meaningful to see such strong engagement from the hypoparathyroidism patient community – the conversations and questions throughout the event reflected a shared optimism about the future of the HP treatment landscape.

22/09/2025

Hopeful news for people living with : The Phase 2 Avail clinical trial of our once-weekly parathyroid hormone (PTH) replacement therapy met its primary endpoint with a 63% responder rate at 12-weeks, and 79% responder rate in the open-label extension. The candidate was generally well-tolerated, and the findings are an important step forward in research for this rare and chronic condition.

We are so thankful to the patients, families, doctors, and research teams who made this study possible. Your dedication brings us closer to simpler, more effective care options.

Learn more about the data and next steps for the investigational once-weekly PTH replacement therapy: https://investors.mbxbio.com/news-releases/news-release-details/mbx-biosciences-announces-once-weekly-canvuparatide-achieved

04/09/2025

We announced today that the first participant has been dosed in the Phase 1 trial of our Precision Endocrine Peptide (PEP) glucagon-like peptide-1 (GLP-1)/ glucose-dependent insulinotropic polypeptide (GIP) co-agonist prodrug for the treatment of .

Thank you to our talented team, whose dedication to improving the lives of patients affected by obesity brought this milestone to fruition.

Read the press release here: https://investors.mbxbio.com/news-releases/news-release-details/mbx-biosciences-doses-first-participant-phase-1-trial-mbx-4291

Address

Website

https://mbxbio.com/

Alerts

Be the first to know and let us send you an email when MBX Biosciences, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic?

Country:

City: